30 Day Trial

Anika Therapeutics Reports 1Q18 Orthobiologic Revenue

Share:

Anika Therapeutics posted 1Q18 orthobiologic revenue of US $19.5MM, -3.6% vs. 1Q17.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.